Founders Capital Management (Texas)’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Founders Capital Management (Texas)’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-71	Closed	-$171	–	435
2023 Q2	$171	Hold	71	–	–	﹤0.01%	391
2023 Q1	$1K	Hold	71	–	–	﹤0.01%	383
2022 Q4	$1K	Sell	71 -186	-72%	-$2.13K	﹤0.01%	373
2022 Q3	$4K	Hold	257	–	–	﹤0.01%	352
2022 Q2	$9K	Hold	257	–	–	0.01%	332
2022 Q1	$11K	Hold	257	–	–	0.01%	267
2021 Q4	$11K	Hold	257	–	–	0.01%	267
2021 Q3	$17K	Hold	257	–	–	0.01%	233
2021 Q2	$20K	Buy	257 +143	+125%	+$8.71K	0.01%	204
2021 Q1	$8K	Hold	114	–	–	0.01%	261
2020 Q4	$4K	Buy	+114	New	+$5.07K	﹤0.01%	282
2020 Q1	$3K	Hold	114	–	–	﹤0.01%	292
2019 Q4	$6K	Buy	114 +57	+100%	+$2.76K	﹤0.01%	288
2019 Q3	$3K	Buy	57 +28	+97%	+$2.01K	﹤0.01%	309
2019 Q2	$3K	Hold	29	–	–	﹤0.01%	318
2019 Q1	$4K	Hold	29	–	–	﹤0.01%	310
2018 Q4	$5K	Hold	29	–	–	0.01%	293
2018 Q3	$7K	Buy	+29	New	+$6.87K	0.01%	267

Other funds holding DMK

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Founders Capital Management (Texas)'s DMK Position: Q3 2023 in Review

Founders Capital Management (Texas) sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2023, closing a stake of 71 shares — an estimated $171 sold.

Founders Capital Management (Texas) first reported a position in DMK in Q3 2018 and held it in 18 quarters. The position peaked at $20K in Q2 2021. 25 funds tracked by Wall St. Rank hold DMK as of Q3 2023.

Founders Capital Management (Texas) reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
Founders Capital Management (Texas) sold 71 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2023, an estimated $171.
Founders Capital Management (Texas) first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2018 and held it in 18 quarters.
Founders Capital Management (Texas)'s DMK Pharmaceuticals Corporation Common Stock position peaked at $20K in Q2 2021.
25 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2023.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2023, filed 10 Oct 2023.